Chapter 12. Haematologic Cancers: Challenges in Developing New Therapeutic Approaches

  1. David Machin3,4,5,
  2. Simon Day6 and
  3. Sylvan Green7
  1. Charles A. Schiffer1 and
  2. Stephen L. George2

Published Online: 17 MAY 2007

DOI: 10.1002/9780470010167.ch12

Textbook of Clinical Trials, Second Edition

Textbook of Clinical Trials, Second Edition

How to Cite

Schiffer, C. A. and George, S. L. (2006) Haematologic Cancers: Challenges in Developing New Therapeutic Approaches, in Textbook of Clinical Trials, Second Edition (eds D. Machin, S. Day and S. Green), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470010167.ch12

Editor Information

  1. 3

    Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 16910, Singapore

  2. 4

    UK Children's Cancer Study Group, University of Leicester, UK

  3. 5

    Medical Statistics Group, School of Health and Related Sciences, University of Sheffield, UK

  4. 6

    Licensing Division, Medicines and Healthcare products Regulatory Agency, Room 13–205 Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK

  5. 7

    Arizona Cancer Centre, Tucson, Arizona, USA

Author Information

  1. 1

    Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA

  2. 2

    Department of Biostatistics and Bioinformatics, CALGB Statistical Center, Duke University Medical Center, Box 2714, Durham, NC 27710, USA

Publication History

  1. Published Online: 17 MAY 2007
  2. Published Print: 24 NOV 2006

ISBN Information

Print ISBN: 9780470010143

Online ISBN: 9780470010167

SEARCH

Keywords:

  • haematologic cancers;
  • acute progranulocytic leukaemia (APL);
  • Disease-free (or relapse-free) survival (DFS);
  • Overall survival (OS) and acute myeloid leukaemia (AML) in older adults;
  • ‘competing risks’ analysis in AML older adults

Summary

This chapter contains sections titled:

  • Introduction

  • Background

  • Improving Therapy for Older Patients with AML

  • Statistical Issues in Design and Analysis

  • Other Considerations

  • Summary

  • References